(Source: AbbVie Inc) AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015 - May 12, 2015 IT STARTS WITH SCIENCE AND ENDS WITH A NEW WAY FORWARD - Abstracts presented further evaluate the safety, efficacy of HUMIRA® (adalimumab) in moderate to severe Crohn's disease, pediatric Crohn's disease and ulcerative colitis - Data examining indirect costs and family burden associated with pediatric Crohn's disease featured in oral presentation - Research presented further assesses the safety, efficacy of VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) with or without ribavirin in genotype 1 chronic hepatitis C virus...
↧